AstraZeneca And Oracle Explore AI To Improve Clinical Trial Recruitment

By Elizabeth Urbanek, Executive Editor

October 20, 2026 | Austin, Texas, and Abu Dhabi, UAE

AstraZeneca and Oracle are exploring how artificial intelligence (AI) and real-world data can help identify eligible clinical trial participants earlier, a development with potential implications for clinical supply forecasting and trial readiness.

The companies announced a nonbinding agreement October 20 to combine AstraZeneca’s scientific, clinical development and regulatory expertise with Oracle’s real-world data, cloud infrastructure and AI-enabled clinical capabilities. Their collaboration will explore opportunities to improve clinical trial recruitment, support earlier diagnosis, strengthen drug-safety monitoring and connect research findings with routine care.

The first program will focus on hypertension care and clinical research in Abu Dhabi, in partnership with healthcare company M42. The companies plan to explore additional projects across the U.S., Middle East and Europe, spanning oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare diseases.

Pascal Soriot, CEO of AstraZeneca, said the collaboration could help clinicians “identify patients sooner, optimise (sic) clinical trials, and generate evidence continuously across the lifecycle of a medicine.”

The agreement is intended to test practical applications of AI and real-world data within clinical workflows. The companies will use deidentified real-world data under privacy and security safeguards, with each proposed project subject to separate legal, regulatory, ethical and institutional review.

Why Clinical Supply Should Care

Patient recruitment is an upstream driver of clinical trial supply demand. Changes in enrollment timing and geographic distribution can affect when investigational medicinal product (IMP) is needed, how much inventory must be available at sites and depots, and when resupply decisions must be made.

If AI-enabled tools help clinical teams identify eligible patients earlier and improve recruitment, supply teams may need to adjust forecasts and inventory plans to reflect changing enrollment patterns. Earlier identification does not guarantee enrollment, however. Screening outcomes, informed consent, site readiness and patient decisions still influence when participants enter a study.

Geographic changes in recruitment can introduce additional planning considerations. If enrollment accelerates at certain sites or shifts among countries, supply teams may need to reassess inventory allocation, distribution schedules and resupply timing. Those decisions must account for product availability, shipment lead times, country-specific requirements and the study protocol.

The operational value lies in how recruitment information reaches the teams responsible for supply decisions. Earlier visibility into enrollment trends could give planners more time to evaluate whether existing inventory will meet anticipated demand, whether shipments need to be brought forward or deferred, and whether manufacturing and packaging schedules remain aligned with the study.

Turning recruitment insights into actionable supply decisions requires coordination between clinical operations and supply planning. Teams need timely, reliable data and a process for translating changes in enrollment assumptions into updated forecasts and inventory requirements.

For clinical supply leaders, the question is not simply whether AI can improve recruitment. It is whether better recruitment intelligence can reach supply teams early enough to support more responsive planning while preserving the inventory buffers needed to protect trial continuity.

The Supply Question

How can clinical supply teams incorporate AI-driven recruitment insights into forecasting and inventory decisions without treating potential participants as confirmed demand?

Related Clinical Supply Leader Editorials

• Can Site Enrollment Data Improve Clinical Trial Forecasts?
• AI in Clinical Supply: From Forecasting to Execution Decisions

About The Author:

Elizabeth Urbanek is the Executive Editor for Clinical Supply Leader, where she works with clinical trial supply and logistics professionals across pharma and biotech to bring real-world perspectives, operational challenges, trends, scientific insights and regulatory strategy to the field.

Before joining life sciences media, Elizabeth spent more than 15 years in broadcast, digital and live-event storytelling, helping highly technical teams communicate complex ideas with clarity and impact. She brings that same approach to clinical supply, creating editorial space for experts to share what is happening across clinical trial operations.

Elizabeth is passionate about connecting people and ideas, identifying emerging themes and showcasing work that can move the clinical supply field forward.